title: Prognostic and predictive markers in pancreatic adenocarcinoma.
abstract: Pancreatic ductal adenocarcinoma is characterized by a poor prognosis and a low median survival, despite improvements observed for many other solid tumours. Intensive research efforts have been undertaken during the last decades to discover new prognostic and treatment predictive biomarkers for pancreatic ductal adenocarcinoma. The mainstay of medical treatment for the disease has been the well-tolerated nucleoside analogue, gemcitabine. The only targeted agent currently used in pancreatic ductal adenocarcinoma patients is the epithelial growth factor receptor inhibitor erlotinib in combination with gemcitabine. Recently, treatment regimens such as a combination of fluorouracil-leucovorin-irinotecan-oxaliplatin (FOLFIRINOX) and the combination of nab-paclitaxel with gemcitabine have been introduced for metastatic pancreatic ductal adenocarcinoma. Although these treatment regimens significantly improve survival of patients, there are no good predictive biomarkers available that can be used to identify who would benefit most from them. Therefore, the search for predictive biomarkers that would facilitate personalization of chemotherapy is highly relevant.
authors.affiliation: Semmelweis University, Second Internal Medicine Department, Gastroenterology Division, Budapest, Hungary.
authors.forename: Nha
authors.initials: N
authors.lastname: Le
authors.affiliation: University of Umeå, Department of Surgical and Perioperative Sciences, Umeå, Sweden. Electronic address: malin.sund@surgery.umu.se.
authors.forename: Malin
authors.initials: M
authors.lastname: Sund
authors.affiliation: University of Pavia, Department of Surgery, IRCCS S. Matteo University Hospital Foundation, Pavia, Italy.
authors.forename: Alessio
authors.initials: A
authors.lastname: Vinci
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018395:CA-19-9 Antigen / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002352:Carrier Proteins / Q000378:metabolism; D055436:Growth Differentiation Factor 15 / Q000378:metabolism; D006801:Humans; D020783:Matrix Metalloproteinase 7 / Q000378:metabolism; D008840:Microfilament Proteins / Q000378:metabolism; D055271:Mucin 5AC / Q000378:metabolism; D055264:Mucin-4 / Q000378:metabolism; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism; D015676:Osteonectin / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002135:Calcium-Binding Proteins; D002352:Carrier Proteins; C502658:FSCN1 protein, human; C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15; C524658:MUC4 protein, human; C524678:MUC5AC protein, human; D008840:Microfilament Proteins; D055271:Mucin 5AC; D055264:Mucin-4; D009363:Neoplasm Proteins; D015676:Osteonectin; C103003:S100P protein, human; C577241:SPARC protein, human; C060932:MMP7 protein, human; D020783:Matrix Metalloproteinase 7
keywords: Chemotherapy; Metastatic pancreatic cancer; Predictive marker; Prognostic marker